Sulfocostunolide A exhibits significant anti-inflammatory activity by inhibiting the production of pro-inflammatory mediators such as nitric oxide and prostaglandin E2 in activated macrophages. It suppresses the expression of key inflammatory enzymes, including inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), making it a potential candidate for the development of treatments for chronic inflammatory diseases. Additionally, it demonstrates moderate cytotoxic effects against certain cancer cell lines, suggesting possible application in oncology research. Its unique sulfonated sesquiterpene lactone structure contributes to enhanced solubility and bioactivity, which may be leveraged in designing novel pharmaceutical agents.